Envista Holdings (NVST) Cash from Financing Activities (2018 - 2026)
Envista Holdings' (NVST) quarterly Cash from Financing Activities came in at -$45.6 million in Q2 2026, down 159.09% year-on-year from $77.2 million in Q2 2025, and down 80.95% quarter-over-quarter from -$25.2 million in Q4 2025.
Envista Holdings (NVST) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Envista Holdings' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at -$45.6 million for Q2 2026.
- On a quarterly basis, Cash from Financing Activities fell 159.09% year-over-year to -$45.6 million in Q2 2026; TTM through Apr 2026 was -$198.9 million, a 67.57% decrease from a year earlier, with the FY2025 full-year figure at -$170.9 million, down 64.8% from the prior year.
- Cash from Financing Activities slipped to -$45.6 million in Q2 2026 per NVST's latest filing, from -$25.2 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $114.5 million in Q3 2023 and bottomed at -$100.5 million in Q3 2024.
- The 5-year median for Cash from Financing Activities is -$1.5 million (2023), against an average of -$11.1 million.
- Across the five-year window, Cash from Financing Activities soared 1813.95% in 2022 and sank 28900.0% in 2025, its largest moves.
- Year by year, Cash from Financing Activities stood at -$68.3 million in 2022, then surged by 104.83% to $3.3 million in 2023, then plunged by 127.27% to -$900000.0 in 2024, then sank by 2700.0% to -$25.2 million in 2025, then plunged by 80.95% to -$45.6 million in 2026.
- Per Business Quant, the three latest NVST Cash from Financing Activities figures stand at -$45.6 million (Q2 2026), -$25.2 million (Q4 2025), and -$41.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn | -133.00 Mn |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn | -287.90 Mn |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn | -414.00 Mn |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn | -13.00 Mn |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn | -255.24 Mn |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn | -164.80 Mn |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn | -75.80 Mn |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn | -50.00 Mn |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn | -48.13 Mn |
| 10 | Envista Holdings | 4.29 Bn | 3.20 Bn | 390.10 Mn | -45.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | -45.60 Mn |
| Apr 3, 2026 | -45.60 Mn |
| Dec 31, 2025 | -25.20 Mn |
| Dec 31, 2025 | -25.20 Mn |
| Sep 26, 2025 | -41.70 Mn |
| Sep 26, 2025 | -41.70 Mn |
| Jun 27, 2025 | -86.40 Mn |
| Jun 27, 2025 | -86.40 Mn |
| Mar 28, 2025 | -17.60 Mn |
| Mar 28, 2025 | -17.60 Mn |
| Dec 31, 2024 | -900,000.00 |
| Dec 31, 2024 | -900,000.00 |
| Sep 27, 2024 | -100.50 Mn |
| Sep 27, 2024 | -100.50 Mn |
| Jun 28, 2024 | 300,000.00 |
| Jun 28, 2024 | 300,000.00 |
| Mar 29, 2024 | -2.60 Mn |
| Mar 29, 2024 | -2.60 Mn |
| Dec 31, 2023 | 3.30 Mn |
| Dec 31, 2023 | 3.30 Mn |